Does the media refer more to ARWR or NAMS?

In the previous week, NewAmsterdam Pharma had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat NewAmsterdam Pharma's score of 0.39 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer NAMS or SMMT?

In the previous week, NewAmsterdam Pharma had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat NewAmsterdam Pharma's score of 0.39 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NAMS or KRYS?

In the previous week, NewAmsterdam Pharma had 12 more articles in the media than Krystal Biotech. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat NewAmsterdam Pharma's score of 0.39 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Krystal Biotech 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IONS or NAMS?

In the previous week, Ionis Pharmaceuticals had 10 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 28 mentions for Ionis Pharmaceuticals and 18 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.39 beat Ionis Pharmaceuticals' score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 8 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to ABVX or NAMS?

In the previous week, NewAmsterdam Pharma had 14 more articles in the media than Abivax. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat NewAmsterdam Pharma's score of 0.39 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

NewAmsterdam Pharma (NAMS) Competitors

$22.80 +0.94 (+4.30%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$22.80 0.00 (-0.02%)

As of 09/11/2026 07:30 PM Eastern

Compare

NAMS vs. ARWR, SMMT, KRYS, IONS, and ABVX

Should you buy NewAmsterdam Pharma stock or one of its competitors? NewAmsterdam Pharma's main competitors and comparable companies include Arrowhead Pharmaceuticals (ARWR), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), Ionis Pharmaceuticals (IONS), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50M	17.43	-$1.63M	-$2.25	N/A
NewAmsterdam Pharma	$7.12M	382.73	-$203.82M	-$2.16	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

In the previous week, NewAmsterdam Pharma had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat NewAmsterdam Pharma's score of 0.39 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals currently has a consensus price target of $99.15, indicating a potential upside of 19.68%. NewAmsterdam Pharma has a consensus price target of $49.73, indicating a potential upside of 118.10%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats Arrowhead Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Summit Therapeutics?

NewAmsterdam Pharma (NASDAQ:NAMS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

NewAmsterdam Pharma has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat NewAmsterdam Pharma's score of 0.39 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Summit Therapeutics	N/A	-168.94%	-141.92%

NewAmsterdam Pharma has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$7.12M	382.73	-$203.82M	-$2.16	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

NewAmsterdam Pharma currently has a consensus target price of $49.73, indicating a potential upside of 118.10%. Summit Therapeutics has a consensus target price of $25.91, indicating a potential upside of 47.63%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Krystal Biotech?

NewAmsterdam Pharma (NASDAQ:NAMS) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NewAmsterdam Pharma has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 12 more articles in the media than Krystal Biotech. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 6 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.32 beat NewAmsterdam Pharma's score of 0.39 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 54.82% compared to NewAmsterdam Pharma's net margin of -3,644.21%. Krystal Biotech's return on equity of 19.34% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Krystal Biotech	54.82%	19.34%	17.65%

Krystal Biotech has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$7.12M	382.73	-$203.82M	-$2.16	N/A
Krystal Biotech	$389.13M	26.40	$204.83M	$7.98	43.48

NewAmsterdam Pharma currently has a consensus target price of $49.73, suggesting a potential upside of 118.10%. Krystal Biotech has a consensus target price of $365.40, suggesting a potential upside of 5.30%. Given NewAmsterdam Pharma's higher possible upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Krystal Biotech beats NewAmsterdam Pharma on 11 of the 15 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Ionis Pharmaceuticals had 10 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 28 mentions for Ionis Pharmaceuticals and 18 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.39 beat Ionis Pharmaceuticals' score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	8 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals has a net margin of -64.76% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus price target of $91.25, suggesting a potential upside of 68.33%. NewAmsterdam Pharma has a consensus price target of $49.73, suggesting a potential upside of 118.10%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

NewAmsterdam Pharma has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.54	-$381.39M	-$3.46	N/A
NewAmsterdam Pharma	$7.12M	382.73	-$203.82M	-$2.16	N/A

Summary

NewAmsterdam Pharma beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Abivax?

Abivax (NASDAQ:ABVX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Abivax has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Abivax presently has a consensus target price of $156.38, suggesting a potential upside of 31.81%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 118.10%. Given NewAmsterdam Pharma's higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

47.9% of Abivax shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abivax has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 14 more articles in the media than Abivax. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat NewAmsterdam Pharma's score of 0.39 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

NewAmsterdam Pharma has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
NewAmsterdam Pharma	$7.12M	382.73	-$203.82M	-$2.16	N/A

Summary

NewAmsterdam Pharma beats Abivax on 10 of the 15 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.73B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-10.56	14.18	274.95	25.29
Price / Sales	382.73	1,477.55	656.56	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	3.82	15.12	10.33	6.20
Net Income	-$203.82M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-10.24%	-4.34%	-3.32%	-2.35%
1 Month Performance	-18.07%	-0.02%	-0.41%	-2.77%
1 Year Performance	-5.75%	40.64%	19.21%	7.63%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	2.8642 of 5 stars	$22.80 +4.3%	$49.73 +118.1%	-14.3%	$2.73B	$7.12M	N/A	100	News Coverage Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.5181 of 5 stars	$82.74 +0.4%	$98.42 +18.9%	+178.8%	$11.65B	$829.45M	N/A	400	Analyst Forecast
SMMT Summit Therapeutics	3.6748 of 5 stars	$14.16 +4.0%	$24.07 +70.0%	-5.6%	$11.30B	N/A	N/A	110	Positive News Analyst Forecast
KRYS Krystal Biotech	3.1583 of 5 stars	$363.84 +1.2%	$365.40 +0.4%	+140.4%	$10.77B	$389.13M	45.59	210	Positive News
IONS Ionis Pharmaceuticals	3.1998 of 5 stars	$59.88 -0.8%	$94.15 +57.2%	-15.3%	$9.95B	$944M	N/A	1,402	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. ARWR, SMMT, KRYS, IONS, and ABVX

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Krystal Biotech?

Summary

How does NewAmsterdam Pharma compare to Ionis Pharmaceuticals?

Summary

How does NewAmsterdam Pharma compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. ARWR, SMMT, KRYS, IONS, and ABVX

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Do insiders and institutionals have more ownership in ARWR or NAMS?

Which has preferable earnings & valuation, ARWR or NAMS?

Is ARWR or NAMS more profitable?

Does the media refer more to ARWR or NAMS?

Do analysts prefer ARWR or NAMS?

Which has more volatility and risk, ARWR or NAMS?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Which has more volatility & risk, NAMS or SMMT?

Does the media prefer NAMS or SMMT?

Is NAMS or SMMT more profitable?

Which has higher valuation & earnings, NAMS or SMMT?

Do analysts rate NAMS or SMMT?

Do insiders & institutionals believe in NAMS or SMMT?

Summary

How does NewAmsterdam Pharma compare to Krystal Biotech?

Do institutionals & insiders have more ownership in NAMS or KRYS?

Which has more volatility & risk, NAMS or KRYS?

Does the media prefer NAMS or KRYS?

Is NAMS or KRYS more profitable?

Which has preferable earnings and valuation, NAMS or KRYS?

Do analysts recommend NAMS or KRYS?

Summary

How does NewAmsterdam Pharma compare to Ionis Pharmaceuticals?

Does the media refer more to IONS or NAMS?

Is IONS or NAMS more profitable?

Do insiders & institutionals hold more shares of IONS or NAMS?

Which has more risk and volatility, IONS or NAMS?

Do analysts recommend IONS or NAMS?

Which has higher earnings & valuation, IONS or NAMS?

Summary

How does NewAmsterdam Pharma compare to Abivax?

Is ABVX or NAMS more profitable?

Do analysts rate ABVX or NAMS?

Do institutionals and insiders hold more shares of ABVX or NAMS?

Which has more risk & volatility, ABVX or NAMS?

Does the media refer more to ABVX or NAMS?

Which has stronger valuation & earnings, ABVX or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools